Generic Name:
Blinatumomab
Project Status:
Complete
Therapeutic Area:
MRD+ ALL Resubmission
Manufacturer:
Amgen Canada Inc
Brand Name:
Blincyto
Project Line:
Reimbursement Review
Project Number:
PC0204-000
NOC Date:
Details
Strength:
38.5 mcg
Tumour Type:
Leukemia
Indications:
Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL)
Funding Request:
Patients with Philadelphia chromosome-negative CD19 positive B-precursor acute lymphoblastic leukemia (ALL) in first or second hematologic complete remission with minimal residual disease (MRD) greater than or equal to 0.1%
Review Status:
Complete
Sponsor:
Amgen Canada Inc
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
Patients with Philadelphia chromosome-negative CD19 positive B-precursor acute lymphoblastic leukemia (ALL) in first or second hematologic complete remission with minimal residual disease (MRD) greater than or equal to 0.1%
pERC Meeting:
Final Recommendation Issued: